Your browser doesn't support javascript.
loading
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
Jädersten, Martin; Boriskina, Ksenia; Lindholm, Carolin; Weström, Simone; Cavelier, Lucia; Hellström-Lindberg, Eva; Mielke, Stephan; Tobiasson, Magnus.
Afiliação
  • Jädersten M; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Boriskina K; Center for Hematology and Regenerative Medicine, Insitution for Medicine, Huddinge, Sweden.
  • Lindholm C; Centre for Allogeneic Stem Cell Transplantation, Stockholm, Sweden.
  • Weström S; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Cavelier L; Center for Hematology and Regenerative Medicine, Insitution for Medicine, Huddinge, Sweden.
  • Hellström-Lindberg E; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala Universitet, Uppsala, Sweden.
  • Mielke S; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala Universitet, Uppsala, Sweden.
  • Tobiasson M; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Leuk Lymphoma ; 63(3): 755-758, 2022 03.
Article em En | MEDLINE | ID: mdl-34775885
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas Idioma: En Ano de publicação: 2022 Tipo de documento: Article